132 related articles for article (PubMed ID: 17906297)
1. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Morschhauser F; Seymour JF; Kluin-Nelemans HC; Grigg A; Wolf M; Pfreundschuh M; Tilly H; Raemaekers J; van 't Veer MB; Milpied N; Cartron G; Pezzutto A; Spencer A; Reyes F; Dreyling M
Ann Oncol; 2008 Feb; 19(2):247-53. PubMed ID: 17906297
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Robertson MJ; Kahl BS; Vose JM; de Vos S; Laughlin M; Flynn PJ; Rowland K; Cruz JC; Goldberg SL; Musib L; Darstein C; Enas N; Kutok JL; Aster JC; Neuberg D; Savage KJ; LaCasce A; Thornton D; Slapak CA; Shipp MA
J Clin Oncol; 2007 May; 25(13):1741-6. PubMed ID: 17389337
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.
Igarashi T; Kobayashi Y; Ogura M; Kinoshita T; Ohtsu T; Sasaki Y; Morishima Y; Murate T; Kasai M; Uike N; Taniwaki M; Kano Y; Ohnishi K; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Tobinai K;
Ann Oncol; 2002 Jun; 13(6):928-43. PubMed ID: 12123339
[TBL] [Abstract][Full Text] [Related]
5. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
Oh Y; Herbst RS; Burris H; Cleverly A; Musib L; Lahn M; Bepler G
J Clin Oncol; 2008 Mar; 26(7):1135-41. PubMed ID: 18309949
[TBL] [Abstract][Full Text] [Related]
6. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
Renner C; Zinzani PL; Gressin R; Klingbiel D; Dietrich PY; Hitz F; Bargetzi M; Mingrone W; Martinelli G; Trojan A; Bouabdallah K; Lohri A; Gyan E; Biaggi C; Cogliatti S; Bertoni F; Ghielmini M; Brauchli P; Ketterer N;
Haematologica; 2012 Jul; 97(7):1085-91. PubMed ID: 22315486
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Wang ML; Blum KA; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Zhang L; Baher L; Cheng M; Lee D; Beaupre DM; Rule S
Blood; 2015 Aug; 126(6):739-45. PubMed ID: 26059948
[TBL] [Abstract][Full Text] [Related]
8. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.
Rolland D; Ribrag V; Haioun C; Ghesquieres H; Jardin F; Bouabdallah R; Franchi P; Briere J; De Kerviler E; Chassagne-Clement C; Raponi M; Houlgatte R; Jais JP; Thieblemont C
Cancer Chemother Pharmacol; 2010 Mar; 65(4):781-90. PubMed ID: 19960345
[TBL] [Abstract][Full Text] [Related]
10. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Arcaini L; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Cabeçadas J; Campo E; Pileri SA; Biyukov T; Patturajan M; Casadebaig Bravo ML; Trnĕný M;
Br J Haematol; 2018 Jan; 180(2):224-235. PubMed ID: 29193019
[TBL] [Abstract][Full Text] [Related]
11. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
[TBL] [Abstract][Full Text] [Related]
12. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Rademaker-Lakhai JM; Beerepoot LV; Mehra N; Radema SA; van Maanen R; Vermaat JS; Witteveen EO; Visseren-Grul CM; Musib L; Enas N; van Hal G; Beijnen JH; Schellens JH; Voest EE
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4474-81. PubMed ID: 17671132
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
15. Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma.
Schwartzberg L; Hermann R; Flinn I; Flora D; Hsi ED; Hamid O; Shi P; Lin BK; Myrand SP; Nguyen TS; Dreyling M
Br J Haematol; 2014 Jul; 166(1):91-7. PubMed ID: 24673609
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Habermann TM; Lossos IS; Justice G; Vose JM; Wiernik PH; McBride K; Wride K; Ervin-Haynes A; Takeshita K; Pietronigro D; Zeldis JB; Tuscano JM
Br J Haematol; 2009 May; 145(3):344-9. PubMed ID: 19245430
[TBL] [Abstract][Full Text] [Related]
17. A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.
Evens AM; Balasubramanian S; Vose JM; Harb W; Gordon LI; Langdon R; Sprague J; Sirisawad M; Mani C; Yue J; Luan Y; Horton S; Graef T; Bartlett NL
Clin Cancer Res; 2016 Mar; 22(5):1059-66. PubMed ID: 26482040
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF; Pozdnyakova O; Smith SM; LeBlanc M; Friedberg JW
Br J Haematol; 2016 Jan; 172(2):208-18. PubMed ID: 26492567
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors.
Mukohara T; Nagai S; Koshiji M; Yoshizawa K; Minami H
Cancer Sci; 2010 Oct; 101(10):2193-9. PubMed ID: 20707806
[TBL] [Abstract][Full Text] [Related]
20. Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.
Crump M; Leppä S; Fayad L; Lee JJ; Di Rocco A; Ogura M; Hagberg H; Schnell F; Rifkin R; Mackensen A; Offner F; Pinter-Brown L; Smith S; Tobinai K; Yeh SP; Hsi ED; Nguyen T; Shi P; Hahka-Kemppinen M; Thornton D; Lin B; Kahl B; Schmitz N; Savage KJ; Habermann T
J Clin Oncol; 2016 Jul; 34(21):2484-92. PubMed ID: 27217449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
